Clinical Trial Update: Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

View source ↗

Summary

A clinical trial is evaluating high-dose rate brachytherapy combined with immunotherapy and chemotherapy as a second-line treatment for advanced non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: The First People's Hospital of Neijiang | Conditions: Advanced Stage NSCLC, Second-line Treatment | Status: ACTIVE_NOT_RECRUITING